Gemfibrozil improves insulin sensitivity and flow‐mediated vasodilatation in type 2 diabetic patients

Abstract

GF treatment improves both insulin action and flow-mediated vasodilatation in type 2 diabetic patients. The reduction of TG concentration allows the simultaneous correction of two important components of the metabolic syndrome.